| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1690fe33a027d2dc50fda9249bfa2461
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a53456aaa281884da8ec1b02c25f42a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e493dbb326bdb84242fbc9af833f128e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 |
| filingDate |
1992-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa576fd46e8d760aff67ac60c6fc1db2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_753cd486311aa8e275de7342286b810c |
| publicationDate |
1994-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9402144-A1 |
| titleOfInvention |
Use of 7-fluoro-1-methyl-3-methylsulphinyl-4-quinolone in the treatment of angina pectoris |
| abstract |
A method and use are provided for the treatment of angina pectoris in humans, comprising the administration of an effective amount of 7-fluoro-1-methyl-3-methylsulphinyl-4-quinolone to a human in need of such treatment. Preferably the active compound is administered in an amount of at least 50 mg, once a day. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6995173-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2004251003-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1079764-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1079764-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0007595-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20040035302-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6458804-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005000275-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6562838-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6426084-B1 |
| priorityDate |
1992-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |